Sein métastatique HER2+ HER2CLIMB02 (SGNTUC-016) A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Paris
Appareil pulmonaire MS200647-0005 A Multicenter, Double Blind, Randomized,Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer· Protocol MS200647-0005 Paris CATHERINE DANIEL
VADS TrilynX (Debio 1143-SCCHN-301) A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in;combination with platinum-based chemotherapy and standard fractionation intensitymodulated;radiotherapy in patients with locally advanced squamous cell carcinoma of;the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
Appareil pulmonaire AMG 20190009_25004 A Phase 3 Multicenter, Randomized, Open;Label, Active-controlled, Study of AMG 510;Versus Docetaxel for the Treatment of Previously;Treated Locally Advanced and Unresectable or;Metastatic NSCLC Subjects With Mutated;KRAS p.G12C Paris NICOLAS GIRARD
Appareil pulmonaire PAPILLON (61186372NSC3001 ) A Randomized, Open-label Phase 3 Study of Combination Amivantamab and;Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients;with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung;Cancer Paris NICOLAS GIRARD
Appareil pulmonaire ELDERLY Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin with weekly paclitaxel chemotherapy Paris, Saint-Cloud MARIE ANGE MASSIANI, MARIE ANGE MASSIANI
Appareil pulmonaire TROPION-Lung01 (DS1062-A-U301) PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS;DOCETAXEL IN PREVIOUSLY TREATED ADVANCED;OR METASTATIC NON-SMALL CELL LUNG CANCER;WITHOUT ACTIONABLE GENOMIC ALTERATIONS;(TROPION-LUNG01) Paris NICOLAS GIRARD